| Hazard Information | Back Directory | [Uses]
DB0614 is a PROTAC based on Cereblon ligand, which is a selective and potent targeted protein degrader of NEK9 inhibitor. DB0614 can degrade ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2 and ULK1. DB0614 can be used for research of disease or disorder mediated by aberrant kinase activity[1][2].(Blue: Thalidomide-4-OH (HY-103596), Black: linker, Pink: FLT3-IN-17 (HY-148070)) | [IC 50]
CDK6; CDK16/Cyclin Y; ULK1; Aurora Kinase; SIK2; LIMK2 | [References]
[1] SeongShick Ryu, et al. Synthesis and structure-activity relationships of targeted protein degraders for the understudied kinase NEK9[J]. Current Research in Chemical Biology. 2021. 1:100008.
[2] William Thomas Darlow, et al. Discovery of NEK9 and Aurora A PROTACs Using a Proteomics-Based Screening Approach. The Institute of Cancer Research. 2022.
[3] GRAY, Nathanael S. Compounds for targeted protein degradation of kinases. WO2022093742. 2022/093742 |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|